[go: up one dir, main page]

DK3292873T3 - Kombination af vaccination og hæmning af PD-1-vejen - Google Patents

Kombination af vaccination og hæmning af PD-1-vejen Download PDF

Info

Publication number
DK3292873T3
DK3292873T3 DK17001347.8T DK17001347T DK3292873T3 DK 3292873 T3 DK3292873 T3 DK 3292873T3 DK 17001347 T DK17001347 T DK 17001347T DK 3292873 T3 DK3292873 T3 DK 3292873T3
Authority
DK
Denmark
Prior art keywords
vaccination
pathway
inhibition
combination
Prior art date
Application number
DK17001347.8T
Other languages
English (en)
Inventor
Mariola Fotin-Mleczek
Karl-Josef Kallen
Jochen Probst
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54602080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3292873(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curevac Ag filed Critical Curevac Ag
Application granted granted Critical
Publication of DK3292873T3 publication Critical patent/DK3292873T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17001347.8T 2013-02-22 2014-02-21 Kombination af vaccination og hæmning af PD-1-vejen DK3292873T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2013000526 2013-02-22
EP14706481.0A EP2958588B1 (en) 2013-02-22 2014-02-21 Combination of vaccination and inhibition of the pd-1 pathway

Publications (1)

Publication Number Publication Date
DK3292873T3 true DK3292873T3 (da) 2019-06-03

Family

ID=54602080

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17001347.8T DK3292873T3 (da) 2013-02-22 2014-02-21 Kombination af vaccination og hæmning af PD-1-vejen

Country Status (3)

Country Link
EP (3) EP2958588B1 (da)
BR (1) BR122021025267B1 (da)
DK (1) DK3292873T3 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021025267B1 (pt) 2013-02-22 2023-12-05 Curevac Ag Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1
SG10201710472PA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
CA2935878C (en) 2014-03-12 2023-05-02 Curevac Ag Combination of vaccination and ox40 agonists
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
AU2019374818A1 (en) * 2018-11-07 2021-05-27 Modernatx, Inc. RNA cancer vaccines
CN115120716A (zh) * 2019-01-14 2022-09-30 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
CN115811986A (zh) 2020-04-22 2023-03-17 生物技术欧洲股份公司 冠状病毒疫苗
EP4138782A1 (en) * 2020-04-22 2023-03-01 Novartis AG Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetil-15)
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
JP2008516610A (ja) 2004-10-18 2008-05-22 グローブイミューン，インコーポレイテッド 酵母を用いた慢性ｃ型肝炎感染の治療
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
KR101510065B1 (ko) 2005-06-08 2015-04-07 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20100035973A1 (en) 2006-07-17 2010-02-11 Nationwide Children's Hospital, Inc. Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
US20100040614A1 (en) 2006-12-27 2010-02-18 Rafi Ahmed Compositions and methods for the treatment of infections and tumors
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
PT2170959E (pt) * 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
AU2009319701B2 (en) 2008-11-28 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods for the treatment of infections and tumors
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
AU2011252795B2 (en) 2010-05-14 2015-09-03 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
ES2586580T3 (es) 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
EP2638061B1 (en) 2010-11-11 2015-04-22 The University of Hong Kong Soluble pd-1 variants, fusion constructs, and uses thereof
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
BR122021025267B1 (pt) 2013-02-22 2023-12-05 Curevac Ag Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1

Also Published As

Publication number Publication date
EP2958588B1 (en) 2017-08-23
BR122021025267B1 (pt) 2023-12-05
EP3292873A9 (en) 2018-04-25
EP3292873B1 (en) 2019-05-01
EP3292873A1 (en) 2018-03-14
EP2958588A1 (en) 2015-12-30
EP3578200A1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
DK2958588T3 (da) Kombination af vaccination og hæmning af PD-1-reaktionsvejen
DK3292873T3 (da) Kombination af vaccination og hæmning af PD-1-vejen
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3027618T3 (da) Polymorf af syk-hæmmere
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK2968208T3 (da) Behandling af kataplexi
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3071698T3 (da) Excision og indsættelse af stort gen
DK2882496T3 (da) Behandling og diagnosticering af melanom
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3021838T3 (da) Behandling af fedme
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
DK3071215T3 (da) Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension
DK3050883T3 (da) Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
DK2981541T3 (da) Syntese og anvendelse af isotopmærkede glycaner
DK3182962T3 (da) Compositions and uses of amidine derivatives
DK2964255T3 (da) Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
DK3067355T3 (da) Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat
DK3019167T3 (da) Behandling af forhøjede niveauer af eosinophiler og/eller basophiler
SI3293176T1 (sl) Kristalna oblika inhibitorja PDE4